Tags

Type your tag names separated by a space and hit enter

Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.
Biol Blood Marrow Transplant. 2013 Sep; 19(9):1355-60.BB

Abstract

For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50 years and older with AML in complete remission from SIB (n = 82), URD (n = 35), or UCB (n = 80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (P = .22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (P = .009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P = .04) and worse leukemia-free survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P = .03), whereas donor choice had no significant impact on overall survival (P = .73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (P = .26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission.

Authors+Show Affiliations

Service d'Hématologie Greffe, Hôpital Saint-Louis, AP HP, Paris, France; Equipe d'accueil 3518, Hôpital Saint-Louis & Université Paris 7, AP-HP, Paris, France. regis.peffaultdelatour@sls.aphp.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

23791622

Citation

Peffault de Latour, Régis, et al. "Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts After Reduced-intensity Conditioning for Older Patients With Acute Myelogenous Leukemia." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 19, no. 9, 2013, pp. 1355-60.
Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19(9):1355-60.
Peffault de Latour, R., Brunstein, C. G., Porcher, R., Chevallier, P., Robin, M., Warlick, E., Xhaard, A., Ustun, C., Larghero, J., Dhedin, N., Mohty, M., Socié, G., & Weisdorf, D. (2013). Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 19(9), 1355-60. https://doi.org/10.1016/j.bbmt.2013.06.006
Peffault de Latour R, et al. Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts After Reduced-intensity Conditioning for Older Patients With Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2013;19(9):1355-60. PubMed PMID: 23791622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. AU - Peffault de Latour,Régis, AU - Brunstein,Claudio G, AU - Porcher,Raphael, AU - Chevallier,Patrice, AU - Robin,Marie, AU - Warlick,Erica, AU - Xhaard,Alienor, AU - Ustun,Celalettin, AU - Larghero,Jérôme, AU - Dhedin,Nathalie, AU - Mohty,Mohamad, AU - Socié,Gerard, AU - Weisdorf,Daniel, Y1 - 2013/06/18/ PY - 2013/03/21/received PY - 2013/06/07/accepted PY - 2013/6/25/entrez PY - 2013/6/25/pubmed PY - 2014/3/19/medline KW - Acute myeloid leukemia KW - Cord blood KW - Older patients KW - Reduced-intensity conditioning regimen KW - Unrelated donor SP - 1355 EP - 60 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 19 IS - 9 N2 - For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50 years and older with AML in complete remission from SIB (n = 82), URD (n = 35), or UCB (n = 80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (P = .22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (P = .009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P = .04) and worse leukemia-free survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P = .03), whereas donor choice had no significant impact on overall survival (P = .73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (P = .26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission. SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/23791622/Similar_overall_survival_using_sibling_unrelated_donor_and_cord_blood_grafts_after_reduced_intensity_conditioning_for_older_patients_with_acute_myelogenous_leukemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083-8791(13)00253-X DB - PRIME DP - Unbound Medicine ER -